Navigation Links
Marken Appoints New Directors To Board
Date:3/5/2013

RESEARCH TRIANGLE PARK, N.C., March 5, 2013 /PRNewswire/ -- Marken today announced that it has appointed two independent directors to its Board as a result of Marken's recent restructuring completed on December 21, 2012.  The appointment of Timothy C. Tyson and Michael O'Donnell is the next step in Marken's strategy to focus on serving the global life sciences industry.

(Logo:  http://photos.prnewswire.com/prnh/20110930/NY78064LOGO)

Tim Tyson is a veteran leader in the global pharmaceutical market place.  He currently serves as Chairman of the Board of Aptuit LLC, a global pharmaceutical services company based in the US.  He was CEO and President of Valeant Pharmaceuticals Inc. from 2003-2008.  Prior to that, Mr. Tyson held various leadership roles including as President, Global Manufacturing & Supply at GlaxoSmithKline (GSK).  During his 14 years at GSK, he led the Glaxo Dermatology and Cerenex Divisions, the US Marketing Division, and the US Sales Divisions where he launched 32 products, eight of which exceeded $1billion in global sales.  Mr. Tyson is an engineering graduate of the US Military Academy at West Point, and holds a masters degree in public administration from Jackson State University. He has held key positions on the PhRMA Board and the International Society of Professional Engineers (ISPE).

Michael O'Donnell currently serves as Chairman of Verna, a company specializing in infectious control products, and as non-executive Director of Helical Bar plc. a property development firm.  He has served as an independent Director on the Boards of seven companies since 2008 and also acted as a consultant to one of Marken's clients.  Prior to 2008, Mr. O'Donnell was a Managing Director of LGV Capital, a private equity firm, where he worked for more than a decade. He started his career at Morgan Grenfell where he worked for five years after graduating from University College, Dublin with a Bachelor of Commerce degree. 

"We are delighted to welcome Tim and Michael to Marken's Board of Directors," said Wes Wheeler , Marken's Chief Executive Officer.  "These two independent Directors will certainly provide us with an appropriate balance of deep industry and financial experience.  They also bring excellent contacts from the pharmaceutical industry and the UK financial markets, respectively, which will allow us to continue our expansion in the life sciences supply chain market." 

About Marken
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.


'/>"/>
SOURCE Marken
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
2. Marken Opens Branch Office In Seoul, South Korea
3. Marken Announces Global Advisory Board
4. Marken Launches New Global Regulatory Consultation Services
5. Marken Enhances Branch Operations
6. Marken Expands Regulatory And Technical Excellence In Logistics
7. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
8. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
9. Nephros Appoints John C. Houghton as President and Chief Executive Officer
10. Elsevier Appoints New President of Elsevier CPM Resource Center
11. GenWay Biotech Appoints New Vice President of Custom/OEM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):